Abstract
Citations & impact
Impact metrics
Article citations
Photoimmunotherapy for cancer treatment based on organic small molecules: Recent strategies and future directions.
Transl Oncol, 49:102086, 24 Aug 2024
Cited by: 0 articles | PMID: 39181114 | PMCID: PMC11387906
Review Free full text in Europe PMC
The Effect of Photosensitizer Metalation Incorporated into Arene-Ruthenium Assemblies on Prostate Cancer.
Int J Mol Sci, 24(17):13614, 02 Sep 2023
Cited by: 3 articles | PMID: 37686420 | PMCID: PMC10488040
Recent Studies in Photodynamic Therapy for Cancer Treatment: From Basic Research to Clinical Trials.
Pharmaceutics, 15(9):2257, 31 Aug 2023
Cited by: 18 articles | PMID: 37765226 | PMCID: PMC10535460
Review Free full text in Europe PMC
Current Strategies in Photodynamic Therapy (PDT) and Photodynamic Diagnostics (PDD) and the Future Potential of Nanotechnology in Cancer Treatment.
Pharmaceutics, 15(6):1712, 12 Jun 2023
Cited by: 9 articles | PMID: 37376160 | PMCID: PMC10301405
Review Free full text in Europe PMC
Multifunctional Photoactive Nanomaterials for Photodynamic Therapy against Tumor: Recent Advancements and Perspectives.
Pharmaceutics, 15(1):109, 28 Dec 2022
Cited by: 5 articles | PMID: 36678738 | PMCID: PMC9866498
Review Free full text in Europe PMC
Go to all (15) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Photosensitizers in prostate cancer therapy.
Oncotarget, 8(18):30524-30538, 01 May 2017
Cited by: 33 articles | PMID: 28430624 | PMCID: PMC5444762
Review Free full text in Europe PMC
Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
J Environ Pathol Toxicol Oncol, 25(1-2):373-387, 01 Jan 2006
Cited by: 38 articles | PMID: 16566729
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.
Lancet Oncol, 18(2):181-191, 20 Dec 2016
Cited by: 125 articles | PMID: 28007457
Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.
Clin Cancer Res, 14(15):4869-4876, 01 Aug 2008
Cited by: 52 articles | PMID: 18676760 | PMCID: PMC2680073